Astrazeneca plc - ADR
AZN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$293.23B
Close$
Earnings Call Q3 2026
October 30, 2026 - AI Summary
Strong YTD momentum + resilient ex-headwind growth (good)
- Total revenue +7% in the first 9 months; core EPS +14%.
- Underlying strength: excluding Farxiga + Brilinta, revenue +12%, offsetting expected CVRM loss-of-exclusivity headwinds and other pressures.
- Growth was double-digit in Oncology, Rare Disease, and R&I; regionally, U.S. and Europe strong, emerging markets strong; China impacted by volume-based procurement but ex-VBP China +13%.
Pipeline execution accelerated: multiple Phase III positives + new approvals (good/surprising)
- Since Feb full-year results: positive Phase III results from 12 Phase III programs and first approvals for 4 new medicines, including Etcamah in the U.S.
- Total approved new molecular entities now 14; company reiterated ambition of 20 new medicines by 2030.
- Phase III highlights described: tozorakimab (COPD), efzimfotase alfa (HPP), sone-ve ADC (Claudin18.2+ gastric cancer).
- Management quantified opportunity: these readouts imply >$10B non–risk-adjusted peak year sales potential (with much “risk removed” due to positive data).
Oncology franchise momentum + clear “backbone” strategy (good)
- Oncology revenues $21.9B (+16%) in 9M; +17% in Q3.
- Key commercial beats in Q3:
- Tagrisso $2.1B (+12%); adoption of FLAURA2 and continued combination uptake.
- IO growth: Imfinzi +26% and Imjudo +25%; combined >$2B in Q3 for first time.
- Enhertu $969M (+35%); notable U.S. strength (~+50%) and early HER2+ first-line DESTINY-Breast09 traction.
- Surprising/positive R&D-to-commercial linkage: multiple Phase III trials reinforce IO moving earlier and ADCs expanding (e.g., Orpathys+Tagrisso scenarios in EGFR lung cancer; CLARITY-Gastric01 OS benefit for sone-ve).
Exclusive for Stockcircle Pro members
Sign up
$320.50
69.5% upside
Current Fair Value
69.5% upsideUndervalued by 69.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $293.23 Billion |
|---|---|
| Enterprise Value | $320.55 Billion |
| Annual dividend | $3.23 |
| Dividend yield | 1.71% |
| Earnings per Share | $6.6 |
| Beta | 0.21 |
| Outstanding Shares | 1,551,000,000 |
Return
| Return on Equity | 20.79% |
|---|---|
| Return on Assets | 9.03% |
| Return on Invested Capital | 16.92% |
Valuation & Multiples
| P/E Ratio | 27.87 |
|---|---|
| PEG | 1197.92 |
| Price to Sales | 4.85 |
| Price to Book Ratio | 5.91 |
| Enterprise Value to Revenue | 5.22 |
| Enterprise Value to EBIT | 22.5 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
$2.60
Consensus analyst estimateRevenue Estimate
$16.00 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 9, 2027
EPS Estimate
$2.32
Consensus analyst estimateRevenue Estimate
$16.59 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 82.65% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.58%▼ 50.45% |
|---|---|
| Total Invested | $3.93B▼ 97.99% |
| Investors Holding | 541▼ 983.00% |
About AstraZeneca Plc
96,100 employees
CEO: Pascal Soriot
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...